Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM)

Tempus AI, Inc. (NASDAQ:TEM) is among the 12 Best Genomics Stocks to Invest In.

Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM)

TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95. The shares were still rated as a buy by analyst Kyle Mikson. As noted by Canaccord, the sector momentum that started in the latter half of 2025 can continue into 2026, based on a preview of its coverage of life science instruments and diagnostics.

BofA also reduced its price estimate for Tempus AI, Inc. (NASDAQ:TEM), from $90 to $80 on December 15, 2025. Analyst Michael Ryskin reaffirmed a neutral recommendation on the stock. According to the BofA, the change was a component of a more comprehensive upgrade to price objectives for all of the life sciences and diagnostic tool companies that fall under its umbrella. As per the firm, headwinds should lessen, and markets should return to normal in 2026.

BofA further stated that it anticipates a rebound in biopharma spending to provide the biggest boost for the industry. The firm stated that it supports businesses that have more involvement in research and development.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology business. It provides molecular genotyping, polymerase chain reaction profiling, next-generation sequencing diagnostics, and other anatomic and molecular pathology tests to medical professionals, pharmaceutical firms, biotechnology businesses, researchers, and other third parties.

While we acknowledge the risk and potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None